Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: relapse, malignancy and side effect of steroid

“…Furthermore, an early rapid decrease of bone mineral density occurs within several months of starting CST. According to the Guidelines on the Management and Treatment of Glucocorticoid-Induced Osteoporosis of the Japanese Society for Bone and Mineral Research (2014 update) [14], an age of 65 years or older, prednisolone ‡7.5 mg/day (or its equivalent), prior fragility fracture and lumbar bone mineral density <70% of the Young adult mean are all assigned a score ‡3 as single risk factors, therefore drug therapy should be started for subjects with any of these factors. AIP affects mainly middle-aged to elderly males, and >6 months of maintenance CST is necessary to prevent relapse in this study.…”

“…Steroids have side effects, and several studies have reported steroid side effects related to other autoimmune diseases [13][14][15][16][17][18]. AIP affects mainly middle-aged to elderly males.…”

Efficacy of Vitamin K₂ for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases

“…Osteoporosis is particularly serious because it can impair daily activities by leading to critical bone injuries such as vertebral or femoral neck fractures (1)(2)(3)(4). Bisphosphonates were recommended as first-line therapy in a recently revised guideline on the management and treatment of glucocorticoid-induced osteoporosis published by the Japanese Society for Bone and Mineral Research (5).…”

Radioiodine-Associated Exacerbation of Graves' Orbitopathy in the Japanese Population: Randomized Prospective Study

“…The originally recommended dose regimens of PCS starting at approximately 0.5 mg/kg/d, with gradual dis- continuation over approximately 3 months, have exhibited definitive preventive effects (3), but the relatively long duration and high dose lead to concern about adverse events. For example, concerning corticosteroid-induced osteoporosis, corticosteroid therapy longer than 3 months carries a risk of bone fracture and a need for bone-protective treatment (21,22). Higher dosages of corticosteroid were also reported to increase the risk of bone fracture (21).…”

“…For example, concerning corticosteroid-induced osteoporosis, corticosteroid therapy longer than 3 months carries a risk of bone fracture and a need for bone-protective treatment (21,22). Higher dosages of corticosteroid were also reported to increase the risk of bone fracture (21). After RAI therapy, the risk of femoral neck fracture was increased (23).…”